NYSEAMERICAN : ARMP
Armata Pharmaceuticals, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 3.44 USD (Oct 30, 2026, 9:30 AM EDT) · Market cap 127.91M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; and AP-PA03 for Pseudomonas aeruginosa. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
Details
| Name | Armata Pharmaceuticals, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 61 |
| Ceo | Deborah Birx |
| Country | United States |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US04216R1023 |
| Cusip | 04216R102 |
| Cik | 921114 |
| Sic | 2836 |
Key executives
| Name | Title |
|---|---|
| Dr. Deborah L. Birx M.D. | Chief Executive Officer and Director |
| David D. House | Chief Financial Officer |
| Dr. Pierre Kyme Ph.D. | Chief Business Officer |
| Peter Hubbard | Vice President of Operations |
| Bani Tchekanova Ph.D. | Head of Regulatory Strategy and Operations |
Contact
| Address | 5005 McConnell Avenue, Los Angeles, California 90066, United States |
| Phone | 310 665 2928 |
| Website | https://www.armatapharma.com |